Practical AE management with TRODELVY1
Management of diarrhoea
Patients who exhibit an excessive cholinergic response to treatment with TRODELVY (e.g. abdominal cramping, diarrhoea, salivation, etc.) can receive appropriate treatment (e.g. atropine) for subsequent treatments with TRODELVY.1
In the ASCENT trial TRODELVY group,Most instances of diarrhoea occurred within the first 2 cycles and lasted about 1 week3
-
0%Treatment discontinuation due to diarrhoea
-
5%Treatment interruption due to diarrhoea
-
5%Dose reduction due to diarrhoea
All events of Grade 3 diarrhoea in patients treated with TRODELVY were resolved, and no Grade 4 events were reported
ABBREVIATIONS:
AE, adverse event.
REFERENCES:
- TRODELVY (sacituzumab govitecan) Summary of Product Characteristics, July 2023.
- Bardia A, et al. N Engl J Med. 2021;384(16):1529–1541.
- Rugo H, et al. NPJ Breast Cancer. 2022; 8: 98.doi: 10.1038/s41523-022-00467-1.